Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I/II ADVANTAGE trial (phase II part)

J. B. Vermorken, F. Peyrade, J. Krauss, R. Mesía, E. Remenar, T. C. Gauler, U. Keilholz, J. P. Delord, P. Schafhausen, J. Erfán, T. H. Brümmendorf, L. Iglesias, U. Bethe, C. Hicking, P. M. Clement

Research output: Contribution to journalArticle

49 Citations (Scopus)

Fingerprint Dive into the research topics of 'Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I/II ADVANTAGE trial (phase II part)'. Together they form a unique fingerprint.

Medicine & Life Sciences